Related Experiment Video
Updated: Jul 27, 2025
Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
Published on: August 16, 2024
Engineered Extracellular Vesicles with Compound-Induced Cargo Delivery to Solid Tumors
1Department of Biochemistry, School of Medicine, Daegu Catholic University, Daegu 42472, Republic of Korea.
Abstract:
Efficient delivery of functional factors into target cells remains challenging. Although extracellular vesicles (EVs) are considered to be potential therapeutic delivery vehicles, a variety of efficient therapeutic delivery tools are still needed for cancer cells. Herein, we demonstrated a promising method to deliver EVs to refractory cancer cells via a small molecule-induced trafficking system. We generated an inducible interaction system between the FKBP12-rapamycin-binding protein (FRB) domain and FK506 binding protein (FKBP) to deliver specific cargo to EVs. CD9, an abundant protein in EVs, was fused to the FRB domain, and the specific cargo to be delivered was linked to FKBP. Rapamycin recruited validated cargo to EVs through protein-protein interactions (PPIs), such as the FKBP-FRB interaction system. The released EVs were functionally delivered to refractory cancer cells, triple negative breast cancer cells, non-small cell lung cancer cells, and pancreatic cancer cells. Therefore, the functional delivery system driven by reversible PPIs may provide new possibilities for a therapeutic cure against refractory cancers.
Insights
Researchers developed a novel system to deliver therapeutic cargo using extracellular vesicles (EVs) and a small molecule-induced protein interaction. This method enhances EV delivery to refractory cancer cells, offering new therapeutic possibilities for difficult-to-treat cancers.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Research
Background:
- Efficient delivery of therapeutic agents into target cells is a significant challenge in medicine.
- Extracellular vesicles (EVs) show promise as delivery vehicles, but improved tools are needed for targeting cancer cells.
- Refractory cancers, including triple-negative breast, non-small cell lung, and pancreatic cancers, require innovative therapeutic strategies.
Purpose of the Study:
- To develop a novel, inducible system for delivering specific cargo via extracellular vesicles (EVs) to refractory cancer cells.
- To utilize a small molecule-induced protein-protein interaction (PPI) to enhance EV-mediated cargo delivery.
- To demonstrate the functional delivery of EVs loaded with therapeutic cargo to various hard-to-treat cancer cell types.
Main Methods:
- Engineered an inducible interaction system using the FKBP12-rapamycin-binding protein (FRB) domain and FK506 binding protein (FKBP).
- Fused CD9, an EV protein, to the FRB domain and linked specific cargo to FKBP.
- Utilized rapamycin to induce protein-protein interactions, recruiting cargo to EVs for subsequent delivery.
Main Results:
- Successfully demonstrated the recruitment of validated cargo to EVs through the inducible FKBP-FRB interaction system.
- Showcased functional delivery of these engineered EVs to refractory cancer cells, including triple-negative breast cancer, non-small cell lung cancer, and pancreatic cancer cells.
- Validated the efficacy of the small molecule-induced trafficking system for therapeutic cargo delivery.
Conclusions:
- The developed reversible PPI-driven system provides a promising new method for enhancing EV-mediated drug delivery.
- This functional delivery system offers novel therapeutic possibilities for combating refractory cancers.
- The inducible nature of the system allows for controlled cargo loading and targeted delivery to cancer cells.
